vs
Side-by-side financial comparison of Essex Property Trust (ESS) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $479.6M, roughly 1.5× Essex Property Trust). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 17.9%, a 1.2% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 5.5%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 6.0%).
Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ESS vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $479.6M | $708.5M |
| Net Profit | $85.7M | $135.1M |
| Gross Margin | 70.0% | — |
| Operating Margin | 31.7% | 21.6% |
| Net Margin | 17.9% | 19.1% |
| Revenue YoY | 5.5% | 32.0% |
| Net Profit YoY | -71.6% | 15.5% |
| EPS (diluted) | $1.24 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $479.6M | $708.5M | ||
| Q3 25 | $473.3M | $659.9M | ||
| Q2 25 | $469.8M | $603.3M | ||
| Q1 25 | $464.6M | $558.6M | ||
| Q4 24 | $454.5M | $536.6M | ||
| Q3 24 | $450.7M | $533.3M | ||
| Q2 24 | $442.4M | $528.1M | ||
| Q1 24 | $426.9M | $511.0M |
| Q4 25 | $85.7M | $135.1M | ||
| Q3 25 | $172.7M | $111.1M | ||
| Q2 25 | $231.5M | $90.3M | ||
| Q1 25 | $212.8M | $114.6M | ||
| Q4 24 | $301.7M | $117.0M | ||
| Q3 24 | $125.5M | $96.4M | ||
| Q2 24 | $99.0M | $88.4M | ||
| Q1 24 | $285.1M | $102.6M |
| Q4 25 | 70.0% | — | ||
| Q3 25 | 69.2% | — | ||
| Q2 25 | 70.7% | — | ||
| Q1 25 | 69.6% | — | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.5% | — | ||
| Q2 24 | 70.8% | — | ||
| Q1 24 | 69.7% | — |
| Q4 25 | 31.7% | 21.6% | ||
| Q3 25 | 44.5% | 21.5% | ||
| Q2 25 | 59.5% | 20.9% | ||
| Q1 25 | 55.3% | 20.3% | ||
| Q4 24 | 67.0% | 23.4% | ||
| Q3 24 | 28.6% | 21.1% | ||
| Q2 24 | 31.1% | 19.9% | ||
| Q1 24 | 31.0% | 20.4% |
| Q4 25 | 17.9% | 19.1% | ||
| Q3 25 | 36.5% | 16.8% | ||
| Q2 25 | 49.3% | 15.0% | ||
| Q1 25 | 45.8% | 20.5% | ||
| Q4 24 | 66.4% | 21.8% | ||
| Q3 24 | 27.8% | 18.1% | ||
| Q2 24 | 22.4% | 16.7% | ||
| Q1 24 | 66.8% | 20.1% |
| Q4 25 | $1.24 | $4.65 | ||
| Q3 25 | $2.56 | $3.86 | ||
| Q2 25 | $3.44 | $3.10 | ||
| Q1 25 | $3.16 | $3.67 | ||
| Q4 24 | $4.00 | $3.67 | ||
| Q3 24 | $1.84 | $3.01 | ||
| Q2 24 | $1.45 | $2.75 | ||
| Q1 24 | $4.25 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $76.2M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.5B | $459.1M |
| Total Assets | $13.2B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $76.2M | $497.0M | ||
| Q3 25 | $66.0M | $285.4M | ||
| Q2 25 | $58.7M | $46.3M | ||
| Q1 25 | $98.7M | $441.4M | ||
| Q4 24 | $66.8M | $669.4M | ||
| Q3 24 | $71.3M | $656.9M | ||
| Q2 24 | $55.2M | $510.9M | ||
| Q1 24 | $499.0M | $407.0M |
| Q4 25 | — | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.6B | — |
| Q4 25 | $5.5B | $459.1M | ||
| Q3 25 | $5.6B | $293.6M | ||
| Q2 25 | $5.6B | $172.4M | ||
| Q1 25 | $5.6B | $593.6M | ||
| Q4 24 | $5.5B | $825.5M | ||
| Q3 24 | $5.4B | $881.4M | ||
| Q2 24 | $5.5B | $763.6M | ||
| Q1 24 | $5.5B | $671.5M |
| Q4 25 | $13.2B | $2.0B | ||
| Q3 25 | $13.2B | $1.8B | ||
| Q2 25 | $13.2B | $1.6B | ||
| Q1 25 | $13.2B | $1.9B | ||
| Q4 24 | $12.9B | $2.1B | ||
| Q3 24 | $12.6B | $2.1B | ||
| Q2 24 | $12.5B | $1.9B | ||
| Q1 24 | $12.9B | $1.8B |
| Q4 25 | — | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1B | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | 12.53× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $192.7M | ||
| Q3 25 | $342.6M | $246.2M | ||
| Q2 25 | $216.1M | $148.5M | ||
| Q1 25 | $281.5M | $125.8M | ||
| Q4 24 | $1.1B | $190.7M | ||
| Q3 24 | $316.2M | $149.1M | ||
| Q2 24 | $218.9M | $116.4M | ||
| Q1 24 | $314.9M | $152.7M |
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | — | $147.2M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | 28.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 12.53× | 1.43× | ||
| Q3 25 | 1.98× | 2.22× | ||
| Q2 25 | 0.93× | 1.65× | ||
| Q1 25 | 1.32× | 1.10× | ||
| Q4 24 | 3.54× | 1.63× | ||
| Q3 24 | 2.52× | 1.55× | ||
| Q2 24 | 2.21× | 1.32× | ||
| Q1 24 | 1.10× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESS
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
